Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Intravitreal Corticosteroids in the Management of Diabetic Macular Edema.

Literature DB >> 24224143

Intravitreal Corticosteroids in the Management of Diabetic Macular Edema.

Stephen G Schwartz¹, Harry W Flynn, Ingrid U Scott.

Abstract

Diabetic macular edema (DME) remains an important worldwide cause of visual loss. Corticosteroids have a role in the treatment of some patients with advanced or recurrent DME. The best studied steroids for this indication are triamcinolone acetonide, dexamethasone, and fluocinolone acetonide. All steroids are associated with risks of cataract and intraocular pressure elevation. In addition, intravitreal injection of any medication is associated with risks of infectious endophthalmitis, which has led to the investigation of various extended-release steroid implants. At this time, no steroid is approved by the United States Food and Drug Administration (FDA) for the treatment of DME.

Entities: CellLine Chemical Disease Gene Species

Keywords: Diabetic macular edema; dexamethasone; fluocinolone acetonide; randomized clinical trial; triamcinolone acetonide

Year: 2013 PMID： 24224143 PMCID： PMC3820371 DOI： 10.1007/s40135-013-0015-3

Source DB: PubMed Journal: Curr Ophthalmol Rep ISSN： 2167-4868

53 in total

1. Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema.

Authors: Masoud Soheilian; Kiumars Heidari Garfami; Alireza Ramezani; Mehdi Yaseri; Gholam A Peyman
Journal: Retina Date: 2012-02 Impact factor: 4.256

2. Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial.

Authors: Ji Won Lim; Hyo Kyoung Lee; Min Cheol Shin
Journal: Ophthalmologica Date: 2011-10-12 Impact factor: 3.250

3. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema.

Authors: Ingrid U Scott; Allison R Edwards; Roy W Beck; Neil M Bressler; Clement K Chan; Michael J Elman; Scott M Friedman; Craig Michael Greven; Raj K Maturi; Dante J Pieramici; Michel Shami; Lawrence J Singerman; Cynthia R Stockdale
Journal: Ophthalmology Date: 2007-08-15 Impact factor: 12.079

4. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.

Authors: David M Brown; Peter A Campochiaro; Rishi P Singh; Zhengrong Li; Sarah Gray; Namrata Saroj; Amy Chen Rundle; Roman G Rubio; Wendy Yee Murahashi
Journal: Ophthalmology Date: 2010-04-09 Impact factor: 12.079

5. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema.

Authors: Julia A Haller; Baruch D Kuppermann; Mark S Blumenkranz; George A Williams; David V Weinberg; Connie Chou; Scott M Whitcup
Journal: Arch Ophthalmol Date: 2010-03

6. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.

Authors: Michael J Elman; Neil M Bressler; Haijing Qin; Roy W Beck; Frederick L Ferris; Scott M Friedman; Adam R Glassman; Ingrid U Scott; Cynthia R Stockdale; Jennifer K Sun
Journal: Ophthalmology Date: 2011-04 Impact factor: 12.079

7. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.

Authors: Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young-Hee Yoon; Marie-Louise Jacques; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup
Journal: Ophthalmology Date: 2010-04-24 Impact factor: 12.079

8. Intravitreal dexamethasone for diabetic macular edema: a pilot study.

Authors: Carmen K M Chan; Shaheeda Mohamed; Vincent Y W Lee; Timothy Y Y Lai; Mahesh P Shanmugam; Dennis S C Lam
Journal: Ophthalmic Surg Lasers Imaging Date: 2010 Jan-Feb

9. SCORE Study report 3: study design and baseline characteristics.

Authors: Michael S Ip; Neal L Oden; Ingrid U Scott; Paul C VanVeldhuisen; Barbara A Blodi; Maria Figueroa; Andrew Antoszyk; Michael Elman
Journal: Ophthalmology Date: 2009-07-19 Impact factor: 12.079

10. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results.

Authors: C M Lee; R J Olk
Journal: Ophthalmology Date: 1991-10 Impact factor: 12.079

9 in total

1. Diabetic macular edema in proliferative stage treated with anti-vascular endothelial growth factor agent and triamcinolone acetonide by laser-based strategies.

Authors: Gang Qiao; Wan-Jiang Dong; Yan Dai; Zhen-Hua Jiang; Hai-Ke Guo
Journal: Int J Ophthalmol Date: 2017-07-18 Impact factor: 1.779

2. New Drugs and New Posterior Delivery Methods in CME.

Authors: João Rafael de Oliveira Dias; Renata Portella Nunes; Raquel Goldhardt
Journal: Curr Ophthalmol Rep Date: 2017-04-07

Review 3. Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine.

Authors: M Elizabeth Fini; Stephen G Schwartz; Xiaoyi Gao; Shinwu Jeong; Nitin Patel; Tatsuo Itakura; Marianne O Price; Francis W Price; Rohit Varma; W Daniel Stamer
Journal: Prog Retin Eye Res Date: 2016-09-22 Impact factor: 21.198

Review 4. Sustained-release corticosteroid options.

Authors: Mariana Cabrera; Steven Yeh; Thomas A Albini
Journal: J Ophthalmol Date: 2014-07-23 Impact factor: 1.909

5. Comparison of the Effect of Intravitreal Dexamethasone Implant in Vitrectomized and Nonvitrectomized Eyes for the Treatment of Diabetic Macular Edema.

Authors: Sadık Görkem Çevik; Sami Yılmaz; Mediha Tok Çevik; Fatma Düriye Akalp; Remzi Avcı
Journal: J Ophthalmol Date: 2018-04-22 Impact factor: 1.909